Privia Health Group (NASDAQ:PRVA) CFO Sells $30,150.00 in Stock

Key Points

• David Mountcastle, Privia's CFO, sold 1,206 shares on May 4 at $25 under a Rule 10b5‑1 trading plan, lowering his stake to 214,847 shares (a 0.56% decrease); this sale is part of a series of insider dispositions since February that generated sizable proceeds.
• Privia (NASDAQ:PRVA) traded near $24.29 with a 52‑week range of $18.77–$26.51 and a market capitalization of about $3.05 billion; the stock carries a high P/E (~142.9) and analysts' consensus is a Moderate Buy with a $31.31 average price target.

Privia Health Group, Inc. (NASDAQ:PRVA - Get Free Report) CFO David Mountcastle sold 1,206 shares of the firm's stock in a transaction that occurred on Monday, May 4th. The stock was sold at an average price of $25.00, for a total value of $30,150.00. Following the sale, the chief financial officer directly owned 214,847 shares of the company's stock, valued at $5,371,175. This represents a 0.56% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

David Mountcastle also recently made the following trade(s):

• On Friday, May 1st, David Mountcastle sold 7,179 shares of Privia Health Group stock. The stock was sold at an average price of $25.03, for a total value of $179,690.37.
• On Thursday, April 2nd, David Mountcastle sold 5,566 shares of Privia Health Group stock. The stock was sold at an average price of $20.85, for a total value of $116,051.10.
• On Monday, March 16th, David Mountcastle sold 6,391 shares of Privia Health Group stock. The stock was sold at an average price of $22.11, for a total value of $141,305.01.
• On Friday, March 13th, David Mountcastle sold 6,565 shares of Privia Health Group stock. The stock was sold at an average price of $21.52, for a total value of $141,278.80.
• On Thursday, March 12th, David Mountcastle sold 6,453 shares of Privia Health Group stock. The shares were sold at an average price of $21.90, for a total value of $141,320.70.
• On Monday, March 9th, David Mountcastle sold 5,829 shares of Privia Health Group stock. The shares were sold at an average price of $22.84, for a total value of $133,134.36.
• On Friday, March 6th, David Mountcastle sold 5,177 shares of Privia Health Group stock. The shares were sold at an average price of $23.15, for a total value of $119,847.55.
• On Thursday, February 26th, David Mountcastle sold 5,361 shares of Privia Health Group stock. The shares were sold at an average price of $25.00, for a total value of $134,025.00.
• On Friday, February 27th, David Mountcastle sold 7,697 shares of Privia Health Group stock. The shares were sold at an average price of $25.05, for a total value of $192,809.85.

Privia Health Group Stock Performance

Privia Health Group stock traded up $0.05 during mid-day trading on Tuesday, reaching $24.29. The stock had a trading volume of 980,019 shares, compared to its average volume of 874,634. Privia Health Group, Inc. has a fifty-two week low of $18.77 and a fifty-two week high of $26.51. The stock's 50-day simple moving average is $22.64 and its 200-day simple moving average is $23.36. The firm has a market capitalization of $3.05 billion, a PE ratio of 142.88, a price-to-earnings-growth ratio of 1.51 and a beta of 0.96.

Privia Health Group (NASDAQ:PRVA - Get Free Report) last announced its quarterly earnings data on Thursday, February 26th. The company reported $0.25 EPS for the quarter, beating analysts' consensus estimates of $0.04 by $0.21. Privia Health Group had a return on equity of 3.06% and a net margin of 1.08%.The firm had revenue of $541.17 million during the quarter, compared to analysts' expectations of $516.61 million. During the same quarter last year, the firm posted $0.21 earnings per share. The company's revenue for the quarter was up 17.4% compared to the same quarter last year. On average, research analysts forecast that Privia Health Group, Inc. will post 0.37 earnings per share for the current fiscal year.

Institutional Trading of Privia Health Group

A number of large investors have recently bought and sold shares of the company. Vanguard Group Inc. increased its position in Privia Health Group by 5.3% in the third quarter. Vanguard Group Inc. now owns 12,098,933 shares of the company's stock worth $301,263,000 after buying an additional 607,447 shares during the last quarter. Durable Capital Partners LP increased its position in Privia Health Group by 1.8% in the third quarter. Durable Capital Partners LP now owns 11,691,685 shares of the company's stock worth $291,123,000 after buying an additional 203,842 shares during the last quarter. State Street Corp increased its position in Privia Health Group by 1.5% in the second quarter. State Street Corp now owns 4,171,069 shares of the company's stock worth $95,935,000 after buying an additional 61,853 shares during the last quarter. Van Berkom & Associates Inc. increased its position in Privia Health Group by 1.8% in the fourth quarter. Van Berkom & Associates Inc. now owns 3,844,256 shares of the company's stock worth $91,147,000 after buying an additional 69,691 shares during the last quarter. Finally, Geode Capital Management LLC increased its position in Privia Health Group by 1.1% in the fourth quarter. Geode Capital Management LLC now owns 2,814,290 shares of the company's stock worth $66,738,000 after buying an additional 31,204 shares during the last quarter. 94.48% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of equities research analysts have commented on PRVA shares. Wolfe Research set a $31.00 price objective on Privia Health Group in a research note on Tuesday, January 6th. Jefferies Financial Group reissued a "buy" rating and issued a $32.00 price objective on shares of Privia Health Group in a research note on Thursday, February 26th. Weiss Ratings restated a "hold (c)" rating on shares of Privia Health Group in a report on Friday, March 27th. Piper Sandler reiterated an "overweight" rating and set a $36.00 price target on shares of Privia Health Group in a report on Thursday, February 26th. Finally, Barclays lifted their price target on Privia Health Group from $23.00 to $25.00 and gave the stock an "equal weight" rating in a report on Wednesday, March 25th. Eleven investment analysts have rated the stock with a Buy rating and three have issued a Hold rating to the stock. According to MarketBeat.com, Privia Health Group has an average rating of "Moderate Buy" and a consensus price target of $31.31.

Privia Health Group Company Profile

Privia Health Group NASDAQ: PRVA is a physician enablement company that partners with independent physicians, medical groups and health systems to transform the delivery of patient care. Through a clinically integrated network and a proprietary technology platform, the company supports providers in managing population health, delivering coordinated care and optimizing financial performance under both fee-for-service and value-based reimbursement models.

Founded in 2016 and headquartered in McLean, Virginia, Privia Health has rapidly expanded its footprint to serve multiple metropolitan markets across the United States.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.